Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
暂无分享,去创建一个
D. Hansell | A. Wells | D. Abraham | C. Denton | T. Maher | D. Visca | A. de Lauretis | P. Sestini | E. Renzoni | N. Goh | C. Zappala | P. Pantelidis | P. Kelleher | V. Ong | R. Hoyles | Laureen Hector
[1] E. Renzoni,et al. Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis , 2012, International journal of rheumatology.
[2] M. Baron,et al. Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group , 2012, Arthritis care & research.
[3] J. Pope,et al. Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy , 2012, The Journal of Rheumatology.
[4] A. Gabrielli,et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres , 2011, Annals of the rheumatic diseases.
[5] S. Duong-Quy,et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis , 2011, European Respiratory Journal.
[6] T. Moritake,et al. Attenuated lung fibrosis in interleukin 6 knock-out mice after C-ion irradiation to lung. , 2011, Journal of radiation research.
[7] S. Mutsaers,et al. STAT3 in tissue fibrosis: is there a role in the lung? , 2011, Pulmonary pharmacology & therapeutics.
[8] A. de Lauretis,et al. Review Series: Aspects of Interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? , 2011, Chronic respiratory disease.
[9] D. Hansell,et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression , 2010, European Respiratory Journal.
[10] H. Collard,et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. , 2010, American journal of physiology. Lung cellular and molecular physiology.
[11] G. Ferraccioli,et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial , 2010, Arthritis research & therapy.
[12] D. Hansell,et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension , 2009, Thorax.
[13] P. Shah,et al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis , 2009, European Respiratory Journal.
[14] K. Brown,et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. , 2009, Chest.
[15] R. Elashoff,et al. Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma , 2009, The Journal of Rheumatology.
[16] D. Hansell,et al. Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.
[17] D. Hansell,et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. , 2007, Arthritis and rheumatism.
[18] T. Medsger,et al. Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.
[19] J. O’Shea,et al. T(H)-17 differentiation: of mice and men. , 2007, Nature Immunology.
[20] N. Siafakas,et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. , 2006, Chest.
[21] G. La Torre,et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis , 2005, Respiratory research.
[22] F. Sampogna,et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement , 2004, Clinical and experimental immunology.
[23] A. Nicholson,et al. Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts , 2004, Respiratory research.
[24] A. Nicholson,et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. , 2004, Radiology.
[25] Shinichi Sato,et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. , 2004, The Journal of rheumatology.
[26] A. Nicholson,et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.
[27] D. Hosmer,et al. Using Aalen's Linear Hazards Model to Investigate Time-varying Effects in the Proportional Hazards Regression Model , 2002 .
[28] S. Bombardieri,et al. Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients , 2002, Medicine.
[29] Paul J. Friedman,et al. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.
[30] M. Hasegawa,et al. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. , 2001, Journal of dermatological science.
[31] K. Kondo,et al. Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. , 2001, Cytokine.
[32] S. Abe,et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. , 2000, American journal of respiratory and critical care medicine.
[33] L. Glimcher,et al. Lineage commitment in the immune system: the T helper lymphocyte grows up. , 2000, Genes & development.
[34] M. Hasegawa,et al. Elevated Serum KL-6 Levels in Patients with Systemic Sclerosis: Association with the Severity of Pulmonary Fibrosis , 2000, Dermatology.
[35] American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.
[36] David A. Lynch,et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .
[37] A. Silman,et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. , 1999, Arthritis and rheumatism.
[38] M. Fujimoto,et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. , 1998, The Journal of rheumatology.
[39] T. Medsger,et al. Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.
[40] D. Hansell,et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. , 1994, American journal of respiratory and critical care medicine.
[41] Hyung-Sik Kang,et al. IL‐6 induces hepatic inflammation and collagen synthesis in vivo , 1994, Clinical and experimental immunology.
[42] D M Hansell,et al. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. , 1993, AJR. American journal of roentgenology.
[43] R. Strieter,et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.
[44] B. Berman,et al. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. , 1991, The Journal of investigative dermatology.
[45] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[46] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.